BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Week In Review: Biotech Ends Q3 With A Bang


10/3/2006 1:53:58 PM

October 1, 2006 – Biotech had a great week, ending the third quarter on a high note and making it the best quarter of the year so far. The Centient Biotech 200™ rose 92 points or 2.5% to close at 3821.43, outperforming the S&P 500 and Nasdaq. Breadth was in line with the rise in the CBT 200™ index, while the action in the IPO market is picking up considerably. The crop of 2006 biotech IPOs had an especially strong week, led by a 312% increase in Acorda, based on positive news about its MS drug. Among the more seasoned biotech issues, GPC climbed following strong results from its prostate cancer drug; VaxGen moved up after solving its reporting problems, BioCryst announced good avian flu news; and Diversa rose after telling its story at an investor conference. More details...


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES